Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | dihydrofolate reductase DfrA | 0.5217 | 0.5 | 0.5 |
Echinococcus multilocularis | dihydrofolate reductase | 0.5217 | 0.5 | 0.5 |
Schistosoma mansoni | dihydrofolate reductase | 0.5217 | 0.5 | 0.5 |
Mycobacterium leprae | DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) | 0.5217 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 0.5217 | 0.5 | 0.5 |
Chlamydia trachomatis | dihydrofolate reductase | 0.5217 | 0.5 | 0.5 |
Brugia malayi | Dihydrofolate reductase | 0.5217 | 0.5 | 0.5 |
Echinococcus granulosus | dihydrofolate reductase | 0.5217 | 0.5 | 0.5 |
Loa Loa (eye worm) | dihydrofolate reductase | 0.5217 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 20 uM | In vitro inhibition of recombinant HIV-1 protease expressed in E. coli strain D1210 | ChEMBL. | 8126707 |
IC50 (binding) | = 20 uM | In vitro inhibition of recombinant HIV-1 protease expressed in E. coli strain D1210 | ChEMBL. | 8126707 |
IC50 (binding) | = 33 uM | In vitro inhibition of recombinant HIV-2 protease expressed in E. coli strain X90 | ChEMBL. | 8126707 |
IC50 (binding) | = 33 uM | In vitro inhibition of recombinant HIV-2 protease expressed in E. coli strain X90 | ChEMBL. | 8126707 |
K inact (binding) | = 3780 min-1 | The irreversibility of the inactivation reaction of HIV-2 PR was assessed | ChEMBL. | 8126707 |
K inact (binding) | = 3780 min-1 | The irreversibility of the inactivation reaction of HIV-2 PR was assessed | ChEMBL. | 8126707 |
K inact (binding) | = 186000 min-1 | The irreversibility of the inactivation reaction of HIV-1 PR was assessed | ChEMBL. | 8126707 |
K inact (binding) | = 186000 min-1 | The irreversibility of the inactivation reaction of HIV-1 PR was assessed | ChEMBL. | 8126707 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.